Massive study compares four diabetes drugs for heart safety
NCT ID NCT05214573
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at health records from over 386,000 adults with type 2 diabetes and moderate heart disease risk. Researchers compared four common second-line diabetes drugs to see which ones were linked to fewer heart attacks, strokes, and other complications. They also asked patients which treatment outcomes mattered most to them. The goal is to help doctors and patients choose the best medication based on real-world data.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
glucagon-like peptide-1 receptor agonists, SGLT2 inhibitors, DPP-4 inhibitors, sulfonylureas
What this could lead to
If successful, this could help doctors choose the safest second-line diabetes drug for patients with moderate heart disease risk.
What could go wrong
This is an observational study using past data, not a controlled trial, so results may be less reliable. It cannot prove cause and effect.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic Rochester
Rochester, Minnesota, 55905, United States